Our research suggests that TBC1D10B may be regarded as a novel prognostic and predictive marker and therapeutic target for hepatocellular carcinoma patients, including RNA-targeting treatment, such as antisense oligonucleotides or RNA-targeting Cas9. Here, TBC1D10B is linked to hepatocellular carcinoma.